-transparent.png){kind=logo}
Recent discoveries in HIV-1 reverse transcriptase inhibitors. 2020
Shuang-Xi Gu, and
Yuan-Yuan Zhu, and
Chao Wang, and
Hai-Feng Wang, and
Gen-Yan Liu, and
Shuang Cao, and
Lu Huang
Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering & Pharmacy, Wuhan Institute of Technology, Wuhan 430205, China; Pharmaceutical Research Institute, Wuhan Institute of Technology, Wuhan 430205, China; Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou 450001, China. Electronic address: shuangxigu@163.com.
HIV-1 reverse transcriptase inhibitors (RTIs) are indispensable components of highly active antiretroviral therapy (HAART), which has achieved great success in controlling AIDS epidemic in reducing drastically the morbidity and mortality of HIV-infected patients. RTIs are divided into two categories, nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs). In this review, the recent discoveries in NRTIs and NNRTIs, including approved anti-HIV drugs and noteworthy drug candidates in different development stages, are summarized, and their future direction is prospected.
Related Publications
Shuang-Xi Gu, and
Yuan-Yuan Zhu, and
Chao Wang, and
Hai-Feng Wang, and
Gen-Yan Liu, and
Shuang Cao, and
Lu Huang
June 2007,
Applied microbiology and biotechnology,
Shuang-Xi Gu, and
Yuan-Yuan Zhu, and
Chao Wang, and
Hai-Feng Wang, and
Gen-Yan Liu, and
Shuang Cao, and
Lu Huang
January 2008,
Advances in pharmacology (San Diego, Calif.),
Shuang-Xi Gu, and
Yuan-Yuan Zhu, and
Chao Wang, and
Hai-Feng Wang, and
Gen-Yan Liu, and
Shuang Cao, and
Lu Huang
June 2008,
Virus research,
Shuang-Xi Gu, and
Yuan-Yuan Zhu, and
Chao Wang, and
Hai-Feng Wang, and
Gen-Yan Liu, and
Shuang Cao, and
Lu Huang
January 2000,
Advances in pharmacology (San Diego, Calif.),
Shuang-Xi Gu, and
Yuan-Yuan Zhu, and
Chao Wang, and
Hai-Feng Wang, and
Gen-Yan Liu, and
Shuang Cao, and
Lu Huang
January 1992,
Journal of enzyme inhibition,
Shuang-Xi Gu, and
Yuan-Yuan Zhu, and
Chao Wang, and
Hai-Feng Wang, and
Gen-Yan Liu, and
Shuang Cao, and
Lu Huang
January 2006,
Current pharmaceutical design,
Shuang-Xi Gu, and
Yuan-Yuan Zhu, and
Chao Wang, and
Hai-Feng Wang, and
Gen-Yan Liu, and
Shuang Cao, and
Lu Huang
March 2010,
Nihon rinsho. Japanese journal of clinical medicine,
Shuang-Xi Gu, and
Yuan-Yuan Zhu, and
Chao Wang, and
Hai-Feng Wang, and
Gen-Yan Liu, and
Shuang Cao, and
Lu Huang
March 1991,
AIDS research and human retroviruses,
Shuang-Xi Gu, and
Yuan-Yuan Zhu, and
Chao Wang, and
Hai-Feng Wang, and
Gen-Yan Liu, and
Shuang Cao, and
Lu Huang
January 1996,
Biochemistry,
Shuang-Xi Gu, and
Yuan-Yuan Zhu, and
Chao Wang, and
Hai-Feng Wang, and
Gen-Yan Liu, and
Shuang Cao, and
Lu Huang
June 2018,
Expert opinion on emerging drugs,
